# Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

> **NCT06609876** · NA · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 108 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Microwave Ablation
- Donafenib
- Recurrent Tumor

## Interventions

- **PROCEDURE:** Thermal ablation
- **DRUG:** Donafenib

## Key facts

- **NCT ID:** NCT06609876
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609876, "Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06609876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*